SCHEMBL2975853

SCHEMBL2975853

CCCC1=C(c2cccs2)[CH]c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.39
KDM4E B2RXH2 7/20 0.33
ALDH1A1 P00352 7/20 0.33
HPGD P15428 5/20 0.33
RAB9A P51151 4/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
HSD17B10 Q99714 3/20 0.33
TSHR P16473 2/20 0.33
LMNA P02545 1/20 0.33
SREBF2 Q12772 1/20 0.33
PTAFR P25105 1/20 0.32
NPC1 O15118 3/20 0.32
MAPT P10636 2/20 0.32
MAPK1 P28482 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HTT P42858 1/20 0.32
RCE1 Q9Y256 1/20 0.32
GAA P10253 2/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961311 0.77
SCHEMBL2962193 0.77 ADRA1D (0.33) KDM4EALDH1A1RAB9ALMNANPC1
SCHEMBL2975488 0.76 ALDH1A1 (0.41) LTA4HKDM4EALDH1A1HPGDRAB9A
SCHEMBL218029 0.76 ALDH1A1 (0.32) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL2974865 0.75 PTPRC (0.32)
SCHEMBL2959583 0.75
SCHEMBL2973210 0.74 CYP2A6 (0.37) RAB9ADRD2
SCHEMBL2970390 0.74 NR1H2 (0.33)
SCHEMBL2975134 0.73 NR1H2 (0.32)
SCHEMBL2965681 0.73 SMN1; SMN2 (0.33) ALDH1A1RAB9ASMN1; SMN2LMNAPTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US claimed
US-7763562-B2 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-07-27 US disclosed
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US disclosed
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2007-06-14 US disclosed
US-7214747-B2 Phosphorus substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-05-08 US disclosed
US-7214746-B2 Phosphorus bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-05-08 US disclosed
US-20050261449-A1 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENT INC. 2005-11-24 US disclosed
US-20050239981-A1 Phosphorus bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2005-10-27 US disclosed
US-20050239980-A1 Phosphorus substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239981-A1 Phosphorus bridged metallocene compounds for olefin polymerization PYM1, ZNF207, POLL LTA4H 1660/4885KDM4E 1418/4885ALDH1A1 4206/4885
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization AP2M1, AP1M1, PYM1 LTA4H 772/4885KDM4E 2177/4885ALDH1A1 4332/4885
US-20050239980-A1 Phosphorus substituted metallocene compounds for olefin polymerization CCRL2, ARL1, OSBP2 LTA4H 3423/4885KDM4E 3216/4885ALDH1A1 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.